13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
2 檔
33.4%
During the Q2 2024 filing period, Patient Square Capital LP (CIK: 0001819257) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $645.5M across 2 reported positions.
During Q2 2024, Patient Square Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 59.99% | +3.84% | — | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 40.01% | — | — |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 2 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, LQDA) accounted for 33.4% of total reported equity market value during Q2 2024.
During Q2 2024, Patient Square Capital LP's top holdings by market value included ROIV (60.0%)、LQDA (40.0%). The largest single position, ROIV, represented 60.0% of total portfolio value.
In Q2 2024, Patient Square Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.